Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
In a new editorial by ecancermedicalscience Editorial Board member Dr Bishal Gyawali, three examples of low-priced drugs which were rejected or ignored by the oncology community are contrasted with three expensive drugs where persistent optimism remained despite negative clinical trial results.
Dr Gyawali maintains that all drugs should be held to the same rigorous standards – this not only includes skepticism in the absence of sound evidence, but also the suspension of premature judgement as has happened in the cases of repurposed drugs.
Read the full editorial here.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.